GnRH in controlling periovulatory events and subsequent luteal function. This understanding, in turn, has implications 3 To whom correspondence should be addressed for the use of GnRH antagonist therapy for controlled induction The determination of the efficacy of gonadotrophinof follicular development and prevention of premature LH releasing hormone (GnRH) antagonists in blocking the surges, post-coital contraception and control of luteal function luteinizing hormone (LH) surge and luteal function is (Fraser and Bouchard, 1994) . In previous studies, we investiimportant for our understanding of the control of the gated the ability of the GnRH antagonists Detirelix and Antide menstrual cycle and for clinical application. GnRH antagto block the mid-cycle LH surge in the stumptailed macaque onists have failed to block the LH surge reliably in the when administered just prior to the onset of the surge. When non-human primate. The aim of the study was to utilize given to animals in which the serum oestradiol concentrations high dose GnRH antagonist treatment administered during had risen to the full pre-ovulatory quota, the LH surge was the late follicular phase of the menstrual cycle to block the inhibited in only 33% of animals after Detirelix (Fraser, 1990 ) pre-ovulatory LH surge. It was postulated that the LH and in 50% after Antide (Fraser et al., 1991) . The fact that surge would be prevented in all animals, but if this failed there was a tendency for failure of inhibition of the surge to subsequent luteal function would be blocked by continued be associated with animals in which serum oestradiol was suppression of LH, since the early corpus luteum is suscepthighest at the time of onset of treatment led us to suggest that, ible to inhibition by GnRH antagonist treatment. A group in the macaque, the positive feedback effect of oestradiol could of 16 adult female stumptailed macaques (Macaca arctoides) overcome the inhibition of GnRH action. This was in agreement with regular menstrual cycles were selected. The GnRH with the experiments of Knobil and co-workers in rhesus antagonist [N-Ac-D-Nal(2) 1 ,D-pCl-Phe 2 ,D-Pal(3) 3 ,D-(Hci) 6 , monkeys using a number of different approaches (see Hotchkiss Lys(iPr) 8 ,D-Ala 10 ]GnRH (Antarelix) ™ (concentration 10 and Knobil, 1994 for review) and by the inability of GnRH mg/ml) was administered as three daily s.c. injections, at immunoneutralization to prevent the LH surge in the a dose of 1 mg/kg on days 11, 12 and 13 of the follicular stumptailed macaque in contrast to the effectiveness of this phase of the menstrual cycle. Of nine macaques in which approach in non-primates (Fraser et al., 1986) . it was judged that the treatment was commenced within Subsequently, a number of similar studies have been per-1 day of the expected LH surge (serum oestradiol >400 formed in women showing that GnRH antagonist treatment pmol/l), six demonstrated a decline in serum oestradiol could block the LH surge or cause its delay, results which concentrations, a total block of the LH/follicle stimulating appear to differ to some extent from those in the macaque hormone (FSH) surge and inhibition of ovulation as judged (see Fraser and Bouchard, 1994 for review) . by an absence of a rise in progesterone concentrations. In
Another reason for the failure of GnRH antagonist treatment the three other animals in this category, a partial LH surge in macaques to prevent the LH surge in all animals could be occurred, but this failed to result in a functional corpus the result of inadequate inhibition of GnRH. Recently, new luteum. In a further three animals treatment was initiated GnRH antagonists have been developed which have retained on the day of the LH surge, and again there was absence the potency of the previous compounds but have a decreased of a subsequently functional corpus luteum. These results histaminic effect, making them more acceptable clinically, and show that GnRH is involved at the time of the mid-cycle safer to use in high doses in experimental animals. One such LH/FSH surge in the non-human primate. Initiation of high compound is Antarelix ™ , which has an additional advantage dose GnRH antagonist treatment during the periovulatory of high water solubility (Deghenghi et al., 1993) . The availabilperiod abolishes luteal function irrespective of its effects ity of Antarelix allowed us to determine whether the administraupon the LH surge because of its long-term action and tion of a high dose of this GnRH antagonist during the late resultant withdrawal of luteal support. follicular phase of the menstrual cycle could cause reliable Key words: corpus luteum/follicle/LH surge/macaque/ovublockade of the mid-cycle LH surge in the macaque. We lation postulated that, should the LH surge occur, the subsequent function of the corpus luteum would be blocked by the continued presence of the antagonist, since the function of the early corpus luteum is dependent upon LH support in both macaques (Fraser et al., 1987) and women (Dubourdieu et al., 1991) .
Materials and methods
A total of 16 adult female stumptailed macaques (Macaca arctoides) weighing 9-14 kg was selected for study on the basis of having regular menstrual cycles as determined by examination of daily vaginal swabs and measurement of serum concentrations of progesterone and oestradiol-17β. The macaques were housed in individual cages with regular access to common exercise areas. Experiments were carried out in accordance with the Animals (Scientific Procedures) Act, UK, 1986. immediately prior to injection, the GnRH antagonist [N-Ac-DNal(2) 1 ,D-pCl-Phe 2 ,D-Pal(3) 3 , D-(Hci) 6 ,Lys(iPr) 8 ,D-Ala 10 ] GnRH (antarelix; europeptides, argenteuil, France) was dissolved in water containing 5% mannitol to a concentration of 10 mg/ml. Macaques were given three daily injections of the GnRH antagonist administered s.c. in the thigh, at a dose of 1 mg/kg on days 11, 12 and 13 of the follicular phase (first day of menses ϭ day 1).
Blood samples (4 ml) were collected daily throughout the study by femoral or cubital venepuncture without anaesthesia beginning on day 7 of the menstrual cycle and continuing for the next 3 weeks. Thereafter, samples were collected three times per week until the occurrence of the first post-treatment cycle. The blood was allowed to clot overnight, centrifuged at 1000 g for 20 min and the serum was stored at -20°C until required. Serum concentrations of progesterone and oestradiol-17β were measured by established radioimmunoassays (Fraser et al., 1991) , detection limits for progesterone and oestradiol being 0.7 nM and 30 pM respectively. As a measure of short-term response to treatment, serum LH concentrations were determined using an in-vitro bioassay based on the production of testosterone by dispersed mouse Leydig cells as described previously (Fraser et al., 1991) . Sensitivity of this assay was 6 µg LH/l of the NICHHD rhesus monkey pituitary standard RP-1. Follicle stimulating hormone (FSH) was measured using a heterologous radioimmunoassay (Fraser et al., 1986 ) with a detection limit of 2 µg/l NICHHD cyn-FSH-RP1. Figure 1 . The effect of Antarelix injection (1 mg/kg on days 11, 12 Hormone profiles were compared to the normal menstrual pattern and 13 of the cycle) on serum concentrations of oestradiol, obtained from 18 control cycles in our colony collected over the progesterone, follicle stimulating hormone (FSH) and luteinizing previous 3 years, data being plotted around the time of the midhormone (LH) in four macaques in which treatment commenced cycle LH surge. Data for hormone concentrations were subjected to when oestradiol secretion was Ͻ400 pM. Note inhibition of all statistical analysis using one-way analysis of variance for repeated hormones (values are plotted as group means Ϯ SEM). Shaded areas represent mean Ϯ 1 SEM for control cycles (n ϭ 18). measures. The individual transformed means were further examined, where appropriate, using the Newman-Keuls test for pairwise comparisons.
reached a concentration of Ͼ400 pM, the LH surge would be expected to follow in 24 h.
Using this criterion it was found that four out of 16 (25%) Results of the s.c. treatments had been initiated when serum oestradiol was Ͻ400 pM, nine out of 16 (56%) at the correct time (as Although the target time for initiation of treatment was 0-24 h prior to the onset of the surge, it was inevitable that follicular oestradiol had reached Ͼ400 pM), while three out of 16 (19%) had been started when the LH surge was already in progress. development in some of the treated animals had not provided sufficient oestradiol output by the day selected for treatment Cycles were grouped accordingly and results plotted around the day of onset of treatment and the control data plotted while others were more advanced than intended. Since the magnitude of the late follicular phase rise in oestradiol is the according to the equivalent concentration of serum oestradiol at the start of treatment. most accurate predictor of the timing of the onset of the LH surge, examination of serum oestradiol concentrations during
The data for the four animals treated when serum oestradiol was Ͻ400 pM and significantly lower (P Ͻ 0.01) than in the control cycles was used as an index of the accuracy of the onset of treatment. This revealed that, when oestradiol had other groups are shown in Figure 1 . Antagonist administration did not fall significantly, but remained at basal levels for the duration of the cycle. LH concentrations fell significantly (P Ͻ 0.01) by day 2 of treatment and remained suppressed for the remainder of the 5 day period of analysis.
In the remaining three animals in this category, serum oestradiol concentrations did not decline in response to treatment. On day 2 there was a clear rise in LH secretion. The resultant LH surge was 50% of that in control cycles but was not accompanied by a rise in FSH. A small increase in serum progesterone which lasted a few days was detected after the LH surge. Thereafter all hormones were suppressed for the remainder of the cycle, there being no indication of a functional corpus luteum (Figure 3) .
In the three macaques in which treatment coincided with the LH surge, a small progesterone rise occurred during the first few days after treatment, but otherwise pituitary-ovarian function, based on serum concentrations of FSH and oestradiol, was suppressed for the remainder of the cycle (Figure 4) . Mean time to return to ovulation was 52 Ϯ 4 days (mean Ϯ SEM) from end of treatment.
Antarelix was well tolerated, there being no indication of local or systemic histamine reactions.
Discussion
To establish whether GnRH is required during the mid-cycle LH surge, inhibition of GnRH must be delayed until as near as possible to the onset of this anticipated rise. Administration of antagonist at the mid-follicular phase is inappropriate because the hypothalamus is deprived of concentrations of oestradiol required to induce positive feedback and the pituitary is deprived of GnRH priming. In the present study, treatment was initiated in nine macaques at the optimal time during the menstrual cycle. The LH surge was totally abolished in 66% of macaques and attenuated in the remaining animals. This compares with an inhibition in 33% of animals after Detirelix and 50% following Antide treatment (Fraser, 1990; Fraser et al., 1991) . The high dose 3 day treatment with Antarelix most likely explanation for failure to prevent the surge in all animals was because, in treatment failures, the serum oestradiol concentrations had reached the positive feedback threshold induced a fall in serum concentrations of FSH, LH and oestradiol, all of which were significantly lower (P Ͻ 0.001) and had triggered LH release by acting directly upon the pituitary. Administration of GnRH antagonist during the late than pretreatment by day 2. The LH/FSH surge and ovulation, as indicated by serum progesterone concentrations, failed to follicular phase in women highlighted the complication that this treatment was less effective in terms of suppressing occur during that cycle.
In six of the nine macaques treated when oestradiol had follicular function than when the same dose was given earlier in the follicular phase (Ditkoff et al., 1991; Flucker et al. , reached Ͼ400 pM, similar suppressive effects were observed. Results are shown in Figure 2 . Oestradiol declined markedly 1991; Hall et al., 1991) . The relative resistance to GnRH antagonist administration at this time may be due to the status by day 1 (P Ͻ 0.001) and remained significantly suppressed for the duration of the treatment cycle. The LH/FSH surge of the dominant follicle; the closer it is to the time of ovulation, the greater is its ability to develop without serum FSH. This and ovulation were prevented. FSH concentrations were basal at the start of treatment, because of negative feedback as a is likely to have been a factor in those macaques in which a partial LH surge occurred following an inability of treatment result of high serum concentrations of oestradiol; they therefore Figure 3 . The effect of Antarelix injection (1 mg/kg on days 11, 12 and 13 of the cycle) on serum concentrations of oestradiol, and 13 of the cycle) on serum concentrations of oestradiol, progesterone, follicle stimulating hormone (FSH) and luteinizing progesterone, follicle stimulating hormone (FSH) and luteinizing hormone (LH) in three macaques in whom treatment commenced hormone (LH) in three macaques in whom treatment commenced on the day of the LH surge. Note absence of luteal function (values when oestradiol secretion was Ͼ400 pM and continued to rise. Note attenuated LH surge but absence of luteal function (values are are plotted as group means Ϯ SEM). Shaded areas represent mean Ϯ 1 SEM for control cycles (n ϭ 18). plotted as group means Ϯ SEM). Shaded areas represent mean Ϯ 1 SEM for control cycles (n ϭ 18).
Our studies, using regimens likely to result in greater exposure to antagonist, have been associated with a higher to block the rising oestradiol concentrations. On the other hand, in the majority of animals in which oestradiol was number of successful inhibitions, suggesting that the efficacy of treatment is also related to the ability of the antagonist to also in the pre-ovulatory range, the dominant follicle was suppressed, presumably because they were in a less advanced block the effects of GnRH. We now know that in macaques, as in non-primate species, a GnRH surge accompanies the LH stage of maturity. Serum oestradiol concentrations had declined markedly in these animals 1 day after starting GnRH antagonist surge (Xia et al., 1992; Pau et al., 1993) . It is likely that in macaques the achievement of the optimal concentration of treatment. At that time serum concentrations of LH and FSH were not significantly suppressed. It is likely that LH and FSH oestradiol leads to both positive feedback effects at the level of the pituitary and an increase in GnRH release, making did decline after treatment but had recovered to basal values when the blood sample was taken at 24 h, as we observed complete inhibition of the LH surge extremely difficult. Debate as to the role of GnRH during the LH/FSH surge when more detailed analysis was performed (Fraser, 1990) , and that the follicle was susceptible to this deprivation in has continued for many years. Certainly in the macaque, experimental manipulations support a role for oestrogen acting gonadotrophin.
upon the GnRH primed pituitary to induce an LH surge (see luteum during the treatment cycle. This strongly suggests that the LH surge is more difficult to prevent than the GnRH Fraser and Bouchard, 1994; Hotchkiss and Knobil, 1994, for reviews) . During the normal cycle in women there is little mediated drive to the early corpus luteum in the macaque. Although detailed measurements of serum LH concentrations indication for an increase in GnRH pulse frequency (Adams et al., 1994) . It is also clear that an LH surge leading to throughout the luteal phase of the treatment cycle were not performed in the present study, we have previously ovulation can be induced in anovular women and monkeys by an unchanging frequency and dose of exogenous GnRH demonstrated the susceptibility of the early corpus luteum to LH withdrawal by GnRH antagonist treatment during all stages (Hotchkiss and Knobil, 1994) . Using different doses of GnRH antagonist during the early, mid and late follicular phases and of the luteal phase in the stumptailed macaque (Fraser et al., 1986) , findings which have been confirmed in the human during the time of the mid-cycle LH surge, Hall et al. (1994) found that LH could be most consistently suppressed at the (Dubourdieu et al., 1991) . In our previous study (Fraser et al., 1991) , Antide was detectable in the blood for many weeks, time of the LH surge. This led them to suggest that in women there is a decreased release of GnRH during the preovulatory even though pituitary-ovarian function was again becoming active. This suggests that the best indicator of the biological LH surge and that the surge was brought about by other positive influences.
effectiveness of the compound is the suppression of FSH and oestradiol, which we have demonstrated clearly in the present Despite these observations, an essential role for GnRH during the LH/FSH surge in women now seems certain from study. From our current demonstration of suppression of serum concentrations of FSH and oestradiol, it is reasonable to a series of recent studies using GnRH antagonists. These have demonstrated that the LH surge can be abolished or delayed assume that corpus luteum function was abolished as a result of long action of the antagonist via suppression of pituitary during the period of effective GnRH antagonist administration (Ditkoff et al., 1991; Frydman et al., 1992; gonadotrophin secretion. Reduction in luteal function could also be a direct con-1994; Leroy et al., 1994) . In some cycles in women this shortterm GnRH antagonist treatment can cause the dominant sequence of an attenuated LH surge (Chandrasekher et al., 1994) , although our findings of near normal luteal function after follicle to undergo atresia and the LH surge of that cycle is eliminated. In others, the LH surge is delayed until after the attenuation of the LH surge following Antide administration do not support this (Fraser et al., 1991) . We cannot exclude the antagonist treatment has stopped and oestradiol secretion has resumed. It is not known whether treatment outcome is related possibility of a direct action of the GnRH antagonist on the primate ovary, although we doubt the significance of any such to individual differences in clearance of the antagonist, or to the status of the pituitary and dominant follicle, or which effect (Fraser et al., 1996) . Clinically, our results indicate that a long-acting or orally active GnRH antagonist preparation factors influence how long the pituitary-ovarian axis can be put 'on hold'. may function as a method of post-coital fertility control. On the other hand, the use of long-acting preparations should be Additional experiments provide further support for a positive role for GnRH throughout the LH surge in women. When avoided when antagonists are employed for controlling the timing of the LH surge in infertility treatment to prevent GnRH antagonist is administered during the late follicular phase, concomitant administration of oestradiol does not result deleterious effects upon luteal function. in an LH surge (Dubourdieu et al., 1994) . It is assumed that under these circumstances the oestrogen stimulates an
